This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Palm, Zanett: Week's Big Volume Movers

The major sticking point in Wednesday's release was Star Scientific's warning that the results of preliminary testing do not necessarily translate to human testing, and additional work needs to be completed to determine whether the compound will have significant B-amyloid lowering effects in humans. By the end of the session, the stock had lost more than 16%.

Worry over the compound's effect in humans didn't stop one writer on Seeking Alpha from assigning Star Scientific with a price target of $15 to $20. The article, which hypothesized that Star Scientific's compound is not a drug but instead a "nutraceutical" that can be easily tested in humans, was cited as the catalyst for the 13% jump in shares on Thursday.

Some wary traders posting on Twitter called the $15 to $20 price target range for Star Scientific "wild." Several Internet posts made note that the author of the Seeking Alpha article held a long position in Star Scientific. Others noted that Star Scientific, which traded under the ticker symbol STSI until late 2009, has been unprofitable quarter after quarter.

With all the talk of finding a cure for Alzheimer's, heavy insider buying went almost unnoticed by traders. Regulatory filings on Wednesday showed that several Star Scientific insiders bought up large amounts of stock at $2.72 a share, which gave believers in the company another reason for optimism.

-- Written by Robert Holmes in Boston.

Check out all of the week's high-volume, under-$5 stocks at the Dollar Store. View the Dollar Store portfolio on StockPickr.

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CIGX $0.00 0.00%
ZANE $0.07 0.00%
DELL $0.00 0.00%
HPQ $33.07 0.00%
NOK $7.65 0.00%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs